Molecular Profiling of Gliomas and Associated Prognostic Factors

Gliomas represent a heterogeneous group of primary brain tumours whose clinical behaviour varies widely according to underlying molecular alterations. Advances in genomic and epigenomic profiling over the past decade have revealed key driver events, notably mutations in isocitrate dehydrogenase (IDH) genes, codeletion of chromosomal arms 1p and 19q, and alterations in ATRX, CIC and FUBP1. These aberrations form distinct genetic signatures that correlate with patient survival, response to therapy and patterns of tumour infiltration. Epigenetic markers, such as MGMT promoter methylation, further stratify outcomes by predicting sensitivity to alkylating agents. Integrated molecular classification has supplanted purely histological grading by defining biologically coherent subgroups, guiding surgical planning, informing adjuvant treatment decisions and shaping clinical trial design. Novel technologies, including rapid intraoperative diagnostics and machine-learning-driven prognostic tools, promise to refine real-time decision making and personalise care. Together, these developments underscore the global significance of molecular profiling in improving prognostic accuracy, optimising extent of resection, tailoring therapeutic strategies and ultimately enhancing survival for patients with diffuse glioma.

Research from Nature Portfolio

Recent studies have demonstrated the potential of foundation models to transform intraoperative identification of tumour infiltration. A deep-learning framework trained on millions of unlabelled optical microscopy images delivers a normalised infiltration score in under ten seconds on fresh surgical specimens. In a prospective multicentre cohort of diffuse glioma patients, this approach achieved an average area under the receiver operating characteristic curve exceeding 90%, outperforming conventional image-guided adjuncts. Its performance remained robust across diverse molecular subtypes and patient demographics, and generalised without additional training to paediatric and other adult brain tumour types. These findings highlight how artificial intelligence can provide rapid, objective feedback during surgery, support maximal safe resection and reduce early recurrence by detecting microscopic residual disease.

Molecular Profiling of Gliomas and Associated Prognostic Factors publication trend

The graph below shows the total number of articles in molecular profiling of gliomas and associated prognostic factors across all publications each year (not limited to Nature Index journals).

Technical terms

Isocitrate dehydrogenase (IDH) mutation: A genetic alteration in metabolic enzymes that defines prognostically favourable glioma subgroups.

1p/19q codeletion: Concurrent loss of chromosome arms 1p and 19q, characteristic of oligodendrogliomas and predictive of chemotherapy responsiveness.

ATRX mutation: Alteration in a chromatin-remodelling gene associated with telomere maintenance and distinct survival outcomes.

Foundation model: A large-scale deep-learning system pretrained on vast datasets and fine-tuned for specialised tasks, such as rapid tumour detection.

2-Hydroxyglutarate (2HG): An oncometabolite produced by mutant IDH, measurable by mass spectrometry to infer mutation status.

References

1. Foundation models for fast, label-free detection of glioma infiltration. Nature (2024).
2. Prognosis Individualized: Survival predictions for WHO grade II and III gliomas with a machine learning-based web application. npj Digital Medicine (2023).
3. Rapid detection of IDH mutations in gliomas by intraoperative mass spectrometry. Proceedings of the National Academy of Sciences of the United States of America (2024).
4. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget (2012).
5. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?. Radiation Oncology (2011).